[go: up one dir, main page]

MX2009009672A - Compuesto 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazina en combinacion con serotonina para la actividad de recaptacion, 5-ht3 y 5-ht1 para el trataiento del dolor o los sintomas residuales en la depresion relacionados con el sueño y la cognicion. - Google Patents

Compuesto 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazina en combinacion con serotonina para la actividad de recaptacion, 5-ht3 y 5-ht1 para el trataiento del dolor o los sintomas residuales en la depresion relacionados con el sueño y la cognicion.

Info

Publication number
MX2009009672A
MX2009009672A MX2009009672A MX2009009672A MX2009009672A MX 2009009672 A MX2009009672 A MX 2009009672A MX 2009009672 A MX2009009672 A MX 2009009672A MX 2009009672 A MX2009009672 A MX 2009009672A MX 2009009672 A MX2009009672 A MX 2009009672A
Authority
MX
Mexico
Prior art keywords
piperazine
pain
depression
treatment
dimethylphenylsulfanyl
Prior art date
Application number
MX2009009672A
Other languages
English (en)
Inventor
Tine Bryan Stensboel
Nicholas Moore
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39564604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009672(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/DK2007/050075 external-priority patent/WO2007144005A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MX2009009672A publication Critical patent/MX2009009672A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona el uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil]pipe razina en el tratamiento del dolor y de los síntomas residuales en la depresión.
MX2009009672A 2007-03-20 2008-03-14 Compuesto 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazina en combinacion con serotonina para la actividad de recaptacion, 5-ht3 y 5-ht1 para el trataiento del dolor o los sintomas residuales en la depresion relacionados con el sueño y la cognicion. MX2009009672A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200700427 2007-03-20
PCT/DK2007/050075 WO2007144005A1 (en) 2006-06-16 2007-06-15 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
PCT/DK2008/050063 WO2008113359A2 (en) 2007-03-20 2008-03-14 1- [2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition

Publications (1)

Publication Number Publication Date
MX2009009672A true MX2009009672A (es) 2009-12-15

Family

ID=39564604

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009672A MX2009009672A (es) 2007-03-20 2008-03-14 Compuesto 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazina en combinacion con serotonina para la actividad de recaptacion, 5-ht3 y 5-ht1 para el trataiento del dolor o los sintomas residuales en la depresion relacionados con el sueño y la cognicion.

Country Status (29)

Country Link
US (1) US8664225B2 (es)
EP (1) EP2142193B1 (es)
JP (1) JP5371790B2 (es)
KR (1) KR101459168B1 (es)
CN (2) CN101636161A (es)
AR (1) AR065797A1 (es)
AT (1) ATE495745T1 (es)
AU (1) AU2008228638B2 (es)
BR (1) BRPI0808941A2 (es)
CA (1) CA2684571C (es)
CL (1) CL2008000795A1 (es)
CO (1) CO6220962A2 (es)
CY (1) CY1111183T1 (es)
DE (1) DE602008004643D1 (es)
DK (1) DK2142193T3 (es)
EA (1) EA017058B1 (es)
ES (1) ES2355434T3 (es)
HR (1) HRP20110058T1 (es)
IL (2) IL200956A (es)
MX (1) MX2009009672A (es)
MY (1) MY150448A (es)
NZ (1) NZ579721A (es)
PL (1) PL2142193T3 (es)
PT (1) PT2142193E (es)
RS (1) RS51560B (es)
SI (1) SI2142193T1 (es)
TW (1) TW200848411A (es)
UA (1) UA97392C2 (es)
WO (1) WO2008113359A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE540941T1 (de) * 2006-06-16 2012-01-15 Lundbeck & Co As H 1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperaz n als verbindung mit kombinierter serotoninwiederaufnahme-, 5-ht3- und 5-ht1a- aktivität zur behandlung kognitiver störungen
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
SI2421534T1 (sl) 2009-04-24 2014-11-28 H. Lundbeck A/S Tekoče formulacije soli 1-(2-(2,4-dimetilfenilsulfanil) fenil) piperazina
BR112012003280A2 (pt) 2009-08-24 2017-05-23 H Lundbeck As composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
WO2011136376A1 (ja) * 2010-04-30 2011-11-03 武田薬品工業株式会社 腸溶性錠剤
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
BR112015006075B1 (pt) * 2012-09-19 2022-10-04 Sandoz Ag Composto cristalino, composição farmacêutica, uso do composto cristalino, hidrato cristalino do bromidrato de vortioxetina, método para a preparação do hidrato cristalino de bromidrato de vortioxetina, método para a preparação do composto cristalino e uso do hidrato cristalino de bromidrato de vortioxetina
US20160200698A1 (en) 2013-09-12 2016-07-14 Hangzhou Pushai Pharmaceutical Technology Co., Ltd Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CA2933733A1 (en) 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
EP3099669A1 (en) 2014-01-31 2016-12-07 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
CN104059030B (zh) 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
CN105198837B (zh) * 2014-06-09 2018-05-04 上海医药工业研究院 一种沃替西汀氢溴酸盐晶体及其制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN106279066A (zh) * 2015-05-22 2017-01-04 天津药物研究院有限公司 一种氢溴酸沃替西汀晶体的纯化方法
CN106556663B (zh) * 2015-09-30 2018-05-29 成都弘达药业有限公司 一种1-[2-(2,4-二甲基苯基硫烷基)苯基]哌嗪或其盐的检测方法
CN109311833B (zh) 2016-06-16 2022-11-04 广东东阳光药业有限公司 二芳基硫醚哌嗪类化合物及其制备方法和用途
TW201806599A (zh) 2016-07-01 2018-03-01 Ｈ 朗德貝克公司 用於快速開始抗抑鬱作用之給藥方案
SMT202200073T1 (it) * 2017-04-25 2022-03-21 H Lundbeck As Processo per la produzione di vortioxeti-na hbr di forma alfa
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
AU2002351734A1 (en) * 2001-12-20 2003-07-09 H. Lundbeck A/S Aryloxyphenlyl and arylsulfanylphenyl derivatives
ATE540941T1 (de) * 2006-06-16 2012-01-15 Lundbeck & Co As H 1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperaz n als verbindung mit kombinierter serotoninwiederaufnahme-, 5-ht3- und 5-ht1a- aktivität zur behandlung kognitiver störungen

Also Published As

Publication number Publication date
US20110009422A1 (en) 2011-01-13
AU2008228638B2 (en) 2012-09-20
BRPI0808941A2 (pt) 2014-08-19
RS51560B (sr) 2011-06-30
DE602008004643D1 (de) 2011-03-03
MY150448A (en) 2014-01-30
AR065797A1 (es) 2009-07-01
CA2684571C (en) 2012-08-14
IL200956A (en) 2015-05-31
JP2010521501A (ja) 2010-06-24
DK2142193T3 (da) 2011-03-28
CA2684571A1 (en) 2008-09-25
TW200848411A (en) 2008-12-16
CN103948597A (zh) 2014-07-30
KR101459168B1 (ko) 2014-11-07
EP2142193B1 (en) 2011-01-19
CN101636161A (zh) 2010-01-27
US8664225B2 (en) 2014-03-04
NZ579721A (en) 2011-07-29
KR20090125251A (ko) 2009-12-04
ES2355434T3 (es) 2011-03-25
ATE495745T1 (de) 2011-02-15
IL238068A0 (en) 2015-05-31
WO2008113359A3 (en) 2008-11-13
CL2008000795A1 (es) 2008-09-26
JP5371790B2 (ja) 2013-12-18
CY1111183T1 (el) 2015-06-11
HRP20110058T1 (hr) 2011-03-31
EA017058B1 (ru) 2012-09-28
WO2008113359A2 (en) 2008-09-25
IL200956A0 (en) 2010-05-17
AU2008228638A1 (en) 2008-09-25
PL2142193T3 (pl) 2011-04-29
EP2142193A2 (en) 2010-01-13
EA200970870A1 (ru) 2010-04-30
CO6220962A2 (es) 2010-11-19
SI2142193T1 (sl) 2011-03-31
UA97392C2 (ru) 2012-02-10
PT2142193E (pt) 2011-02-02

Similar Documents

Publication Publication Date Title
MX2009009672A (es) Compuesto 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazina en combinacion con serotonina para la actividad de recaptacion, 5-ht3 y 5-ht1 para el trataiento del dolor o los sintomas residuales en la depresion relacionados con el sueño y la cognicion.
TNSN08460A1 (en) 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
UA99611C2 (ru) Способ лечения дефицита внимания с гиперактивностью (adhd) и применение 4-[2-(4-метилфенилсульфанил)фенил]пиперидина для производства лекарственного средства
NI201000093A (es) Toalla para llevar puesta
NZ582284A (en) Carbamoyl-cyclohexanes for treating acute mania
TN2012000038A1 (en) New compositions of 1-[-2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
NZ599757A (en) The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders
EA201070918A1 (ru) Применение ранолазина для лечения сердечно-сосудистых заболеваний
NZ601735A (en) Antibody with binding specificity for Nedd4 protein for reducing influenza infectivity
AU2016202490A1 (en) 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
EA200970798A1 (ru) Композиция для лечения диабета 2 типа
CN202908122U (zh) 一种桌枕
CN202234361U (zh) 一种枕套
ECSP067104A (es) Uso de lingados de receptor en terapia
AR056154A1 (es) Procedimiento de preparacion de 8-fluoro-naftalen-1-ilamina y el uso de esta en la obtencion de un intermediario de sintesis de 7-{4-[4-(8-fluoro-naftalen-1-il)-piperazin-1-il]-butoxi}-3, 4-dihidro-1h-[1, 8]naftiridin-2-ona
UA33149U (ru) Способ лечения аритмий у пациентов с малыми структурными аномалиями сердца
BRMU8500493U (pt) base semiflexivel para colchões
AU322016S (en) Portable collapsible chin rest for medical use
RU2011110108A (ru) Способ пластики передней стенки гортани и трахеи пекторальным лоскутом с двойной кожной площадкой, армированным пластиной из пористого никелида титана

Legal Events

Date Code Title Description
FG Grant or registration